Business
Sernova Highlights Achievements of the HemAcure Hemophilia Cell Therapy Program Presented at ASGCT
(via TheNewswire) Sernova's Cell Pouch transplanted with Factor VIII corre...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Highlights Achievements of the HemAcure Hemophilia Cell Therapy Program Presented at ASGCT(via TheNewswire)\n \n \nSernova's Cell Pouch transplanted with Factor VIII corrected human cells shows robust functional blood clotting improvement demonstrating a novel first-in-class ex vivo gene therapy cell-based approach for the treatment of hemophilia A\n\n \n \nLONDON, ONTARIO - TheNewswire - May 19, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, highlights positive results associated with the development of a novel, safe cell therapy approach, including our proprietary Cell Pouch(TM), for the treatment of hemophilia A as presented on May 15, 2020, by the Horizon 2020 HemAcure Consortium at the American Society of Gene and Cell Therapy's 23rd Annual Meeting (ASGCT).\n\n\n \nThe aim of the HemAcure three-year project was to develop a permanent safe therapeutic solution for those living with hemophilia A in the form of a novel ex vivo gene therapy, cell-based approach within Sernova's proprietary Cell Pouch. This combination therapy strives to permanently replace missing clotting human factor VIII (FVIII) in the patient's own Blood Outgrowth Endothelial Cells (BOECs) transplanted into the Cell Pouch. These corrected cells are to function to release FVIII into the bloodstream restoring the ability for blood clotting to occur during periods of bleeding. \n\n\n \nThe following are highlights of the results presented\n\n\n \n\n\n- BOECs were safely isolated and grown from a small sample of circulating peripheral blood of volunteer Hemophilia A patients unable to express the required FVIII for clotting.\n\n\n\n- To regain the function of the BOECs ability to produce clotting FVIII, techniques were successful in safely inserting the gene responsible for the correction and production of human FVIII into the patient's BOECs, and these corrected cells were safely multiplied to increase their number. \n\n\n\n- Tests were conducted to ensure the safety, and the newly corrected BOECs produced enough human FVIII both in the laboratory and in an initial preclinical animal model deficient of FVIII. FVIII blood levels reached up to 10%, a therapeutically relevant level of FVIII. \n\n\n\n- To further test cell dose-response, in the preclinical model of hemophilia A, animals o...